Search
Berberine
go.drugbank.com/drugs/DB04115ApprovedInvestigationalWithdrawnAn alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsNimesulide
go.drugbank.com/drugs/DB04743ApprovedWithdrawnNimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPrenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalDronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primaril...
Synonyms: N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideCategories: Adrenergic alpha-1 Receptor Antagonists, P-glycoprotein inhibitorsLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesOritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalOritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat suscepti...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 InhibitorsPermethrin
go.drugbank.com/drugs/DB04930ApprovedInvestigationalA pyrethroid insecticide commonly used in the treatment of lice infestations and scabies. It is a yellow to light orange-brown, low melt-ing solid or viscous liquid.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: Kwellada-P Lotion, Kwellada-P CRème RinseBelinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalBelinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalPimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalApremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates